In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones

Toxicological Sciences

Volumn 79, Issue 1, 2004, Pages 106-111

  Nerurkar, Pratibha V ^a   Dragull, Klaus ^a   Tang, Chung Shih ^a  

^a UNIVERSITY OF HAWAII AT MANOA   (United States)

Author keywords

7,8 dihydromethysticin; Apoptosis; Desmethoxyyangonin; Kava; Kavalactones; Piper methysticum; Pipermethystine

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALKALOID DERIVATIVE; CASPASE 3; DEMETHOXYYANGONIN; KAVA EXTRACT; LACTONE DERIVATIVE; METHYSTICIN;

ACUTE TOXICITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL MEMBRANE POTENTIAL; CELL STRAIN HEPG2; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DRUG STRUCTURE; ENZYME LOCALIZATION; ENZYME RELEASE; HERBAL MEDICINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER TOXICITY; MITOCHONDRIAL MEMBRANE; PLANT LEAF; PLANT ROOT; PLANT STEM; SCRUB; STRUCTURE ANALYSIS;

ALKALOIDS; ANIMALS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; KAVA; LACTONES; PLANT EXTRACTS; PLANT LEAVES; PLANT STEMS; PYRIDONES; PYRONES; TIME FACTORS;

PIPER METHYSTICUM;

EID: 2442710270     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfh067     Document Type: Article

References (41)

1. Bilia, A. R., Gallon, S., and Vincieri, F. F. (2002). Kava-kava and anxiety: Growing knowledge about the efficacy and safety. Life Sci. 70, 2581-2597.
2. Blasche, W., S. Ebel, E. Hackenthal, U. Holzgrabe, J. Reichling, and H.D. Höltje, eds. (1994). Hagers Handbuch der Pharmazeutischen Praxis Bd 6: Drogen P-Z. Piper methysticum, pp. 201-221.
3. Bundesanstalt für Arzneimittel und Medizinprodukte. (2002). Abwehr von Arzneimittelrisiken, Stufe II: Kava-kava (Piper methysticum)-haltige und Kavain-haltige Arzneimittel einschliesslich homöopathischer Zubereitungen mit einer Endkonzentration his einschliesslich D4. Bescheid vom 14.06.2002 an Pharmazeutische Unternehmer. Bonn, Germany. www. bfarm.de/de/Arzneimittel/amℐcher/stufenpl/Besch-Kava-Final.pdf.
4. Centers for Disease Control and Prevention. (2003). Hepatic toxicity possibly associated with kava-containing products-United States, Germany, and Switzerland, 199-2002. JAMA 289, 36-37.
5. Clough, A. R., Jacups, S. P., Wang, Z., Burns, C. B., Bailie, R. S., Cairney, S. J., Collie, A., Guyula, T., McDonald, S. P., and Currie, B. J. (2003). Health effects of kava. use in an eastern Arnhem Land Aboriginal community. Intern. Med. J. 33, 336-340.
6. Currie, B. J., and Clough, A. R. (2003). Kava hepatotoxicity with western herbal products: Does it occur with traditional kava use? Med J. Aust. 178, 421-422.
7. Dragull, K., Yoshida, W. Y., and Tang, C.-S. (2003). Piperidine alkaloids from Piper methysticum. Phytochemistry 63, 193-198.
8. Feierman, D. E., Mehrikov, Z., and Zhang, J. (2002). The paradoxical effect of acetaminophen on CYP3A4 activity and content in transfected HepG2 cells. Arch. Biochem. Biophys. 398, 109-117.
9. Food and Drug Administration. (2002). FDA Consumer advisory. http://vm. cfsan.fda.gov/~dms/addskava.html (accessed: 17 July 2003).
10. Gergely, P., Jr., Grossman, C., Niland, B., Puskas, F., Neupane, H., Allam, F., Banki, K., Phillips, P. E., and Perl, A. (2002). Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 46, 175-190.
11. Government of Samoa. (1998). Government of Samoa. Department of Trade, Commerce and Industry Trade and Investment Promotion Unit. March 1998. Kava Production. Available at: www.tradeinvestsamoa.ws/investing_in_ samoa/sector§udies/agricultural↘c/kava.htm. Accessed: 9 October 2003.
12. Gow, P. J., Connelly, N. J., Hill, R. L., Crowley, P., and Angus, P. W. (2003). Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J. Aust. 178, 442-443.
13. Humberston, C. L., Akhtar, J., and Krenzelok, E. P. (2003). Acute hepatitis induced by kava kava. J. Toxicol. 41, 109-113.
14. Johnson, B. M., Qui, S.-X., Zhang, S., Zhang, F., Burdette, J. E., Yu, L., Bolton, J. L., and van Breemen, R. B. (2003). Identification of novel electrophilic metabolites of Piper methysticum Forst. (kava). Chem. Res. Toxicol. 16, 733-740.
15. Keller, F., and Klohs, M. W. (1963). A review of the chemistry and pharmacology of the constituents of Piper methysticum. Lloydia 26, 1-15.
16. Kim, J.-S., He, L., and Lemasters, J. J. (2003). Mitochondrial permeability transition: A commom pathway to necrosis and apoptosis. Biochem. Biophys. Res. Commun. 304, 463-470.
17. Klohs, M. W. (1967). Chemistry of kava. Psychopharmacol. Bull. 4, 10.
18. Lebot, V., Merlin, M., and Lindstrom, L. (1997). Kava-the Pacific Elixir: the Definitive Guide to its Ethnobotany, History, and Chemistry. Yale University Press, New Haven, CT.
19. Lemasters, J. J., Nieminen, A.-L., Qian, T., Trost, L. C., Elmore, S. P., Nishimura, Y., Crowe, R. A., Cascio, W. E., Bradham, C. A., Brenner, D. A., et al. (1998). The mitochondrial permeability transition in cell death: A common mechanism in necrosis, apoptosis, and autophagy. Biochim. Biophys. Acta 66, 177-196.
20. Malsch, U., and Kieser, M. (2001). Efficacy of kava-kava. in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl) 157, 277-283.
21. Mathews, J. D., Riley, M. D., Fejo, L., Munoz, E., Milns, N. R., Gardner, I. D., Powers, J. R., Ganygulpa, E., and Gununuwawuy, B. J. (1988). Effects of the heavy usage of kava on physical health: Summary of a pilot survey in an aboriginal community. Med. J. Aust. 148, 548-555.
22. Mathews, J. M., Etheridge, A. S., and Black, S. R. (2002). Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos. 30, 1153-1157.
23. Moulds, R. F., and Malani, J. (2003). Kava: Herbal panacea or liver poison? Med. J. Aust. 178, 451-453.
24. Mukherjee, S. B., Das, M., Sudhandiran, G., and Shaha, C. (2002). Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes. J. Biol. Chem. 277, 24717-24727.
25. O'Brien, T., Babcock, G., Cornelius, J., Dingeldein, M., Talaska, G., Warshawsky, D., and Mitchell, K. (2000). A comparison of apoptosis and necrosis induced by hepatotoxins in HepG2 cells. Toxicol. Appl. Pharmacol. 164, 280-290.
26. Osseni, R. A., Rat, P., Bogdan, A., Warnet, J. M., and Touitou, Y. (2000). Evidence of prooxidant and antioxidant action of melatonin on human liver cell line HepG2. Life Sci. 68, 387-399.
27. Prakash, A. S., Pereira, T. N., Reilly, P. E., and Seawright, A. A. (1999). Pyrrolizidine alkaloids in human diet. Mutat. Res. 443, 53-67.
28. Regula, K. M., Ens, K., and Krishenbaum, L. A. (2003). Mitochondria-assisted cell suicide: A license to kill. J. Mol. Cell Cardiol. 35, 559-567.
29. Russmann, S., Barguil, Y., Cabalion, P., Kritsanida, M., Duhet, D., and Lauterburg, B. H. (2003). Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur. J. Gastroenterol. Hepatol. 15, 1033-1036.
30. Russmann, S., Lauterburg, B. H., and Helbling, A. (2001). Kava hepatotoxicity. Ann. Intern. Med. 135, 68-69.
31. Shao, Y., He, K., Zheng, B., and Zheng, Q. (1998). Reversed-phase high-performance liquid chromatographic method for quantitative analysis of the six major kavalactones in Piper methysticum. J. Chromatogr. A 825, 1-8.
32. Singh, Y. N., and Devkota, A. K. (2003). Aqueous kava extracts do not affect liver function tests in rats. Planta Med 69, 496-499.
33. Singh, Y. N., and Singh, N. N. (2002). Therapeutic potential of using kava in the treatment of anxiety disorders. CNS Drugs 16, 731-734.
34. Smith, R. M. (1979). Pipermethystine, a novel pyridone alkaloid. Tetrahedron 35, 437-439.
35. Smith, R. M. (1983). Kava lactones in Piper methysticum from Fiji. Phytochemistry 22, 1055-1056.
36. Stickel, F., Baumüller, H.-M., Seitz, K., Vasilakis, D., Seitz, G., Seitz, H. K., and Schuppan, D. (2003). Hepatitis induced by kava (Piper methysticum rhizoma). J. Hepatol. 39, 62-67.
37. Stoller, R. (2000). Liver damage and kava extracts. Schweizerische Arztezeitung 81, 1335-1336.
38. Strahl, S., Ehret, V., Dahm, H. H., and Maier, K. P. (1998). Necrotizing hepatitis after taking herbal remedies. Dtsch. Med. Wochensch. 123, 1410-1414.
39. Ueda, S., Masutani, H., Nakamura, H., Tanaka, T., Ueno, M., and Yodoi, J. (2002). Redox control of cell death. Antioxid. Redox. Signal 4, 405-414.
40. Whitton, P. A., Lau, A., Salisbury, A., Whitehouse, J., and Evans, C. S. (2003). Kava lactones and the kava-kava controversy. Phytochemistry 64, 673-679.
41. Wilkening, S., Stahl, F., and Bader, A. (2003). Comparison of primary human hepatocytes and hepatoma cell line HEPG2 with regard to their biotransformation properties. Drug Metab. Dispos. 31, 1035-1042.